# Clinical Trials Data BRAF - Document 41

# The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01688232

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Adult patient with newly diagnosed colorectal cancer.\n\* Patient with signed informed consent.\n\* Follow up made by the clinical center for inclusion or by a medical team in relation with the center.\n\nExclusion Criteria:",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Adult patient with newly diagnosed colorectal cancer.",

Question:  
Based on the following clinical trial information, would a patient with a BRAF gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, there is no mention of BRAF gene mutation status as either an inclusion or exclusion criterion. Therefore, a patient with a BRAF gene mutation would not be automatically excluded or included based solely on that mutation. The key criteria for inclusion are being an adult patient with newly diagnosed colorectal cancer and having signed informed consent. To determine eligibility, the patient should further verify with the trial's specific conditions or consult with the clinical trial team for more details about any additional genetic considerations.